



US 20210054067A1

(19) **United States**(12) **Patent Application Publication**
Tremblay et al.(10) **Pub. No.: US 2021/0054067 A1**(43) **Pub. Date: Feb. 25, 2021**(54) **ANTIBODIES AGAINST KIDNEY
ASSOCIATED ANTIGEN 1 AND ANTIGEN
BINDING FRAGMENTS THEREOF****C07K 16/30** (2006.01)**C07K 16/00** (2006.01)**A61K 38/06** (2006.01)**A61K 39/395** (2006.01)(71) Applicant: **ADC THERAPEUTICS SA,**
EPALINGES (CH)**A61K 45/06** (2006.01)**C07K 16/18** (2006.01)**A61K 47/68** (2006.01)(72) Inventors: **Gilles Bernard Tremblay, La Prairie**
(CA); Anna N. Moraitis, Laval (CA);
Traian Sulea, Kirkland (CA); Mario
Filion, Longueuil (CA)(52) **U.S. Cl.****CPC** **C07K 16/28** (2013.01); **C07K 2317/515**
(2013.01); **C07K 16/3038** (2013.01); **C07K**
16/3069 (2013.01); **C07K 16/00** (2013.01);
A61K 38/06 (2013.01); **A61K 39/39558**
(2013.01); **A61K 45/06** (2013.01); **C07K 16/18**
(2013.01); **C07K 16/30** (2013.01); **A61K**
47/6861 (2017.08); **A61K 47/6869** (2017.08);
C07K 2317/24 (2013.01); **C07K 2317/34**
(2013.01); **C07K 2317/55** (2013.01); **C07K**
2317/56 (2013.01); **C07K 2317/567** (2013.01);
C07K 2317/92 (2013.01); **C07K 2317/21**
(2013.01); **C07K 2317/565** (2013.01); **C07K**
2317/51 (2013.01); **G01N 33/57484** (2013.01)(21) Appl. No.: **16/707,482**(22) Filed: **Dec. 9, 2019****Related U.S. Application Data**(63) Continuation of application No. 15/811,545, filed on
Nov. 13, 2017, now Pat. No. 10,597,450, which is a
continuation of application No. 15/137,368, filed on
Apr. 25, 2016, now Pat. No. 9,828,426, which is a
continuation of application No. 14/558,186, filed on
Dec. 2, 2014, now Pat. No. 9,393,302, which is a
continuation of application No. 14/036,204, filed on
Dec. 10, 2013, now Pat. No. 8,937,163, filed as
application No. PCT/CA2012/000296 on Mar. 28,
2012.(60) Provisional application No. 61/470,063, filed on Mar.
31, 2011, provisional application No. 61/533,346,
filed on Sep. 12, 2011.**Publication Classification**(51) **Int. Cl.****C07K 16/28** (2006.01)**G01N 33/574** (2006.01)**ABSTRACT**

Antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.

Specification includes a Sequence Listing.